Table 1

Drugs investigated in PsA randomised controlled trials published in 2015–2018

Therapeutic compoundArticles/abstracts (n)Drug targetPopulation
Biological DMARDs
Golimumab1TNFcsDMARD/NSAID-IR
Etanercept1MTX+DMARD-naive
Adalimumab biosimilar (CT-P13)1csDMARD-IR
Etanercept biosimilar (CHS-0214)1csDMARD-IR
Ixekizumab10IL-17AcsDMARD-IR/TNFi-IR
Secukinumab5NSAID-IR/mixed csDMARD/TNFi-IR
ABT-1221TNF/IL-17AcsDMARD/TNFi-IR
Ustekinumab1IL-12/23Patients with active enthesitis
Risankizumab1IL-23–19pNSAID/csDMARD/TNFi-IR
Guselkumab1csDMARD/TNFi-IR
Clazakizumab1IL-6NSAID/csDMARD-IR
Abatacept1CD80/86csDMARD/TNFi-IR
Targeted synthetic DMARDs
Apremilast5PDE4csDMARD-IR/TNFi-IR/csDMARD-naive
Tofacitinib2JAK-1/2/3csDMARD-IR/TNFi-IR
Filgotinib1JAK-1csDMARD-IR
  • csDMARD, conventional synthetic disease-modifying antirheumatic drug; DMARD, disease-modifying antirheumatic drug; IL, interleukin; IR, insufficient responders; JAK, Janus kinase; MTX, methotrexate; NSAID, non-steroidal anti-inflammatory drug; PDE4, phosphodiesterase-4; PsA, psoriatic arthritis; TNF, tumour necrosis factor; TNFi, TNF inhibitor.